GT201000064A - Formulaciones galénicas de alisquireno - Google Patents
Formulaciones galénicas de alisquirenoInfo
- Publication number
- GT201000064A GT201000064A GT201000064A GT201000064A GT201000064A GT 201000064 A GT201000064 A GT 201000064A GT 201000064 A GT201000064 A GT 201000064A GT 201000064 A GT201000064 A GT 201000064A GT 201000064 A GT201000064 A GT 201000064A
- Authority
- GT
- Guatemala
- Prior art keywords
- dosage form
- oral dosage
- alisquiren
- galenic formulations
- solid oral
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 239000006186 oral dosage form Substances 0.000 abstract 3
- 239000007787 solid Substances 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UNA FORMA DE DOSIFICACIÓN ORAL SÓLIDA COMPACTADA CON RODILLO QUE COMPRENDE UNA CANTIDAD TERAPÉUTICAMENTE EFECTIVA DE ALISQUIRENO, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, EN DONDE EL INGREDIENTE ACTIVO ESTÁ PRESENTE EN UNA CANTIDAD MAYOR DEL 38 POR CIENTO EN PESO, CON BASE EN EL PESO TOTAL DE LA FORMA DE DOSIFICACIÓN ORAL, ASÍ COMO A UN PROCESO PARA PREPARAR LA FORMA DE DOSIFICACIÓN ORAL SÓLIDA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97589407P | 2007-09-28 | 2007-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201000064A true GT201000064A (es) | 2012-03-30 |
Family
ID=40377181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201000064A GT201000064A (es) | 2007-09-28 | 2010-03-17 | Formulaciones galénicas de alisquireno |
Country Status (22)
Country | Link |
---|---|
US (1) | US20110033533A1 (es) |
EP (2) | EP2205232A2 (es) |
JP (1) | JP5378384B2 (es) |
KR (1) | KR20100076996A (es) |
CN (1) | CN101808630A (es) |
AR (1) | AR068539A1 (es) |
AU (1) | AU2008303504C1 (es) |
BR (1) | BRPI0817586A2 (es) |
CA (1) | CA2697229A1 (es) |
CL (1) | CL2008002828A1 (es) |
CO (1) | CO6270216A2 (es) |
GT (1) | GT201000064A (es) |
MA (1) | MA31768B1 (es) |
MX (1) | MX2010003260A (es) |
MY (1) | MY148266A (es) |
NZ (1) | NZ584005A (es) |
PE (1) | PE20091203A1 (es) |
RU (1) | RU2483718C2 (es) |
TN (1) | TN2010000120A1 (es) |
TW (1) | TWI436760B (es) |
WO (1) | WO2009040373A2 (es) |
ZA (1) | ZA201001144B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2724746A1 (en) * | 2008-05-23 | 2009-11-26 | Teva Pharmaceuticals Industries Ltd. | Aliskiren monofumarate and processes for preparation thereof |
TW201136582A (en) | 2010-03-16 | 2011-11-01 | Novartis Ag | Improved pharmaceutical compositions of aliskiren and methods of delivery |
TR201002256A1 (tr) | 2010-03-24 | 2011-10-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Stabil aliskiren formülasyonları |
EP2382969A1 (en) | 2010-04-30 | 2011-11-02 | Sanovel Ilac Sanayi ve Ticaret A.S. | Multicoated Aliskiren formulations |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
US6521647B2 (en) * | 2000-04-04 | 2003-02-18 | Pfizer Inc. | Treatment of renal disorders |
AU2002226365A1 (en) * | 2000-12-01 | 2002-06-11 | Novartis Ag | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction |
RU2183116C1 (ru) * | 2001-07-10 | 2002-06-10 | Жаров Олег Владимирович | Фармацевтическая композиция, обладающая болеутоляющим, противовоспалительным, антипиретическим и спазмолитическим действием |
US20040266743A1 (en) * | 2003-05-09 | 2004-12-30 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and a renin inhibitor |
AR048431A1 (es) * | 2004-03-17 | 2006-04-26 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
US20050220865A1 (en) * | 2004-04-02 | 2005-10-06 | Koleng John J | Compressed composition comprising magnesium salt |
MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
CA2605771A1 (en) * | 2005-04-27 | 2006-11-02 | Novartis Ag | Methods of treating atherosclerosis |
WO2007056324A2 (en) * | 2005-11-08 | 2007-05-18 | Novartis Ag | Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent |
TW200804241A (en) * | 2006-02-24 | 2008-01-16 | Novartis Ag | New salt |
GB0605688D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
EP1891937A1 (en) * | 2006-08-25 | 2008-02-27 | Novartis AG | Galenic formulations of aliskiren |
US20100130616A1 (en) * | 2006-11-09 | 2010-05-27 | Novartis Ag | Salt of aliskiren with orotic acid |
EP1972335A1 (en) * | 2007-03-23 | 2008-09-24 | Krka | Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof |
US20100209480A1 (en) * | 2007-09-28 | 2010-08-19 | Ralf Altenburger | Galenical formulations of organic compounds |
-
2008
- 2008-09-24 EP EP08804674A patent/EP2205232A2/en not_active Withdrawn
- 2008-09-24 CN CN200880108854A patent/CN101808630A/zh active Pending
- 2008-09-24 EP EP12188621A patent/EP2548553A1/en not_active Withdrawn
- 2008-09-24 CA CA2697229A patent/CA2697229A1/en not_active Abandoned
- 2008-09-24 PE PE2008001663A patent/PE20091203A1/es not_active Application Discontinuation
- 2008-09-24 MX MX2010003260A patent/MX2010003260A/es active IP Right Grant
- 2008-09-24 MY MYPI2010000722A patent/MY148266A/en unknown
- 2008-09-24 AR ARP080104136A patent/AR068539A1/es unknown
- 2008-09-24 KR KR1020107009195A patent/KR20100076996A/ko not_active Application Discontinuation
- 2008-09-24 CL CL2008002828A patent/CL2008002828A1/es unknown
- 2008-09-24 RU RU2010116530/15A patent/RU2483718C2/ru not_active IP Right Cessation
- 2008-09-24 TW TW097136655A patent/TWI436760B/zh not_active IP Right Cessation
- 2008-09-24 US US12/679,088 patent/US20110033533A1/en not_active Abandoned
- 2008-09-24 JP JP2010526278A patent/JP5378384B2/ja not_active Expired - Fee Related
- 2008-09-24 NZ NZ584005A patent/NZ584005A/xx not_active IP Right Cessation
- 2008-09-24 BR BRPI0817586 patent/BRPI0817586A2/pt not_active IP Right Cessation
- 2008-09-24 AU AU2008303504A patent/AU2008303504C1/en not_active Ceased
- 2008-09-24 WO PCT/EP2008/062769 patent/WO2009040373A2/en active Application Filing
-
2010
- 2010-02-17 ZA ZA2010/01144A patent/ZA201001144B/en unknown
- 2010-03-17 GT GT201000064A patent/GT201000064A/es unknown
- 2010-03-19 TN TNP2010000120A patent/TN2010000120A1/fr unknown
- 2010-04-08 MA MA32758A patent/MA31768B1/fr unknown
- 2010-04-19 CO CO10045478A patent/CO6270216A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200922546A (en) | 2009-06-01 |
MX2010003260A (es) | 2010-04-29 |
MA31768B1 (fr) | 2010-10-01 |
JP5378384B2 (ja) | 2013-12-25 |
AU2008303504B2 (en) | 2012-03-22 |
BRPI0817586A2 (pt) | 2015-03-31 |
US20110033533A1 (en) | 2011-02-10 |
AR068539A1 (es) | 2009-11-18 |
PE20091203A1 (es) | 2009-09-11 |
KR20100076996A (ko) | 2010-07-06 |
NZ584005A (en) | 2012-08-31 |
TWI436760B (zh) | 2014-05-11 |
CN101808630A (zh) | 2010-08-18 |
CA2697229A1 (en) | 2009-04-02 |
RU2483718C2 (ru) | 2013-06-10 |
WO2009040373A2 (en) | 2009-04-02 |
WO2009040373A3 (en) | 2009-08-20 |
MY148266A (en) | 2013-03-29 |
AU2008303504C1 (en) | 2013-05-16 |
ZA201001144B (en) | 2011-12-28 |
EP2548553A1 (en) | 2013-01-23 |
JP2010540489A (ja) | 2010-12-24 |
CO6270216A2 (es) | 2011-04-20 |
AU2008303504A1 (en) | 2009-04-02 |
EP2205232A2 (en) | 2010-07-14 |
RU2010116530A (ru) | 2011-11-10 |
CL2008002828A1 (es) | 2009-05-15 |
TN2010000120A1 (en) | 2011-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066807A (es) | Formulaciones galénicas de compuestos orgánicos | |
AR115939A2 (es) | Composición que contiene palmitoil-etanolamida ultra-micronizada | |
AR070731A1 (es) | Composicion farmaceutica para farmacos poco solubles | |
NZ700881A (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
ECSP12011958A (es) | Composiciones farmacéuticas que comprenden ligandos de receptores sigma | |
ECSP10010224A (es) | Formulaciones líquidas de hormona luteinizante (lh). | |
CO6280574A2 (es) | Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia | |
WO2008023016A3 (en) | Galenic formulations of aliskiren | |
ECSP10010052A (es) | Formulaciones galenicas de alisquireno y valsartan | |
NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
MX2010006284A (es) | Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal. | |
TN2015000135A1 (en) | Modified release formulations for oprozomib | |
AR062393A1 (es) | Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor | |
MX2013000694A (es) | Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb. | |
UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
CL2015002466A1 (es) | Formulaciones de compuestos orgánicos | |
CO6640318A2 (es) | Formas de dosificación oral de bendamustina | |
GT201000064A (es) | Formulaciones galénicas de alisquireno | |
AR061233A1 (es) | Formulacion de liberacion prolongada de naltrexona | |
GT201400042A (es) | Compuesto de benzotiazolona | |
AR062239A1 (es) | Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal | |
ECSP11010998A (es) | Formulación galénica que comprende alisquireno y proceso para su preparación mediante granulación de extrusión fundida | |
MA32719B1 (fr) | Formulations galeniques de composes organiques | |
AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno | |
CO6460763A2 (es) | Métodos y formulaciones ectoparasiticidas |